Aligos Therapeutics Completes Enrollment Of HBeAg+ Patients In Its Phase 2 B-SUPREME Trial Of Pevifoscorvir Sodium To Treat Chronic Hepatitis B Virus Infection

Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026SOUTH

Aligos Therapeutics shares are trading higher after the company reported better-than-expected Q2 earnings results.

Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share

8-K filing — Aligos Therapeutics, Inc. (ALGS)

Filed: 2026-08-06 AccNo: 0001171843-26-005294 Size: 269 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits